Benator D A, Kan V, Gordin F M
Division of Infectious Diseases, Washington, DC Veterans Administration Medical Center, Washington DC 20422, USA.
Am J Med Sci. 1997 Jun;313(6):346-51. doi: 10.1097/00000441-199706000-00006.
The nontuberculous mycobacteria are responsible for considerable morbidity in the immunocompromised and immunocompetent host, especially in the older patient with chronic fibrotic or cavitary disease of the lung. Mycobacterium szulgai is a slow growing mycobacterium infrequent in nature and man. Except from a snail and a tropical fish, it has been isolated only from humans and nearly always represents a true pathogen. Three-drug therapy using in vitro susceptibilities as a guide for 12 to 18 months increases the likelihood of success. We present a patient who developed M szulgai pulmonary infection 30 years after an episode of pulmonary tuberculosis. After successful therapy for his M szulgai infection, this patient developed chronic pulmonary histoplasmosis. We review the 25 years of clinical experience with this mycobacteria; particular emphasis is on the presentation and treatment of this very unusual infection.
非结核分枝杆菌在免疫功能低下和免疫功能正常的宿主中均可导致相当高的发病率,尤其是在患有慢性纤维化或空洞性肺部疾病的老年患者中。苏尔加分枝杆菌是一种生长缓慢的分枝杆菌,在自然界和人类中均不常见。除了从一只蜗牛和一条热带鱼中分离出之外,它仅从人类中分离出,并且几乎总是代表一种真正的病原体。以体外药敏试验为指导进行为期12至18个月的三联药物治疗可提高成功的可能性。我们报告一名患者,他在患肺结核30年后发生了苏尔加分枝杆菌肺部感染。在成功治疗其苏尔加分枝杆菌感染后,该患者又患上了慢性肺组织胞浆菌病。我们回顾了对这种分枝杆菌25年的临床经验;特别强调了这种非常罕见感染的临床表现和治疗方法。